多重耐药革兰阴性菌假体周围感染治疗挑战与策略
该叙述性综述检索无日期限制的文献,汇总多重耐药革兰阴性菌所致假体周围感染的手术与抗生素治疗策略。手术以假体取出治愈率高于DAIR但需考虑手术风险,抗生素以β-内酰胺类为一线、宜高剂量延长或持续输注,黏菌素联合β-内酰胺类临床经验最多。
要点
- 假体取出治愈率高于DAIR,但急性PJI中作为择期手术需考虑手术风险。
- β-内酰胺类为一线,宜高剂量、延长或持续输注以优化抗生物膜效果。
- 黏菌素联合β-内酰胺类临床经验最多,氟喹诺酮耐药是突出问题。
核心结论
- MDR-GNB所致PJI管理复杂,因证据有限需个体化选择手术方式与抗菌治疗,平衡临床有效性与毒性风险。
研究设计与样本
- 叙述性综述,检索无日期限制,纳入实验与临床研究,评估MDR-GNB所致PJI的手术与抗生素治疗策略。
主要发现
- 假体取出治愈率高于DAIR,且允许加用局部活性抗生素。
- DAIR可能适用于部分选择患者,但为最具挑战性的场景。
- 抗生素选择受药敏限制,氟喹诺酮耐药是突出问题,多需长期静脉治疗。
- β-内酰胺类为一线,DAIR管理时理想为联合用药,宜高剂量、延长或持续输注。
- 黏菌素联合β-内酰胺类临床经验最多,亦可考虑TMP-SMX、磷霉素或替加环素。
关键数值与推荐
- 假体取出治愈率高于DAIR。
- β-内酰胺类为一线治疗,DAIR时理想为联合用药。
- 黏菌素联合β-内酰胺类为临床经验最多的方案。
- outpatient parenteral antibiotic therapy为有效策略,可减少住院并确保良好结局。
临床怎么用
- MDR-GNB所致PJI需个体化决定手术类型与抗菌方案。
- β-内酰胺类宜高剂量、延长或持续输注以优化抗生物膜效果。
- 可考虑门诊肠外抗菌治疗以减少住院时间。
- 治疗期间建议优化抗生物膜效果并进行药物监测。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Multidrug-resistant Gram-negative bacteria (MDR-GNB) are an increasing cause of periprosthetic joint infection (PJI), limit the available antibiotic options and affect patient outcomes. OBJECTIVES: We reviewed the therapeutic strategies for managing PJI caused by MDR-GNB, including surgical and antibiotic options. SOURCES: We performed a search regarding PJI caused by MDR-GNB without date restrictions, including experimental and clinical studies. CONTENT: Surgery plays a central role in the therapeutic approach to PJI caused by MDR-GNB. Although prosthesis removal provides higher cure rates than debridement, antibiotics, and implant retention (DAIR), also allowing the addition of local active antibiotics, the surgical risks should be considered when using it as an elective procedure in acute PJI. DAIR may be a valid option for selected patients, but this is the most challenging scenario. The selection of antibiotic treatment is limited by antimicrobial susceptibility, with fluoroquinolone resistance being a particular problem, and mostly requires long-term intravenous therapy. β-Lactams represent the first-line therapy, ideally in combination in cases managed with DAIR, and should be used at high doses and in extended/continuous infusion to optimize their anti-biofilm efficacy. Colistin in combination with β-lactams is the therapy with the most substantial clinical experience, although clinicians may also consider the use of trimethoprim-sulfamethoxazole, fosfomycin, or tigecycline depending on their susceptibility. Outpatient parenteral antibiotic therapy is a valid strategy to minimize lengthy hospitalizations while ensuring good outcomes. IMPLICATIONS: The management of PJI caused by MDR-GNB is complex. Because of limited available evidence, an individualized approach is needed regarding the type of surgery and antimicrobial therapy, balancing the clinical effectiveness and toxicity risks. Currently, intravenous β-lactams are commonly the first-line therapy, which should be administered for long periods, mainly in combination. The optimization of the anti-biofilm effects of therapy and drug monitoring during the treatment is advisable.
引用
- Gómez-Junyent J, Lora-Tamayo J, Sorlí L, et al. Challenges and strategies in the treatment of periprosthetic joint infection caused by multidrug-resistant Gram-negative bacteria: a narrative review. Clin Microbiol Infect. 2025. PMID: 40541677. doi:10.1016/j.cmi.2025.06.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。